Loading
Latest filing published 20 Feb 2025 for Arbutus Biopharma Corporation, €2,886.
No signal scores available.
Christopher Naftzger is a declared insider of Arbutus Biopharma Corporation, with filings sourced from SEDI. We count 2 filings; the first trade dates from 31 December 2024 and the latest from 14 February 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
On 20 February 2025 came the latest disclosure, a share grant for €2,886 in Arbutus Biopharma Corporation. This summary is built from SEDI disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations